The National Cancer Institute (NCI) and Sanford Burnham Prebys (SBP) successfully completed the third annual NCI Chemical Biology Consortium (CBC) Symposium on January 31, 2024, at the Sanford Consortium for Regenerative Medicine in La Jolla, California. This year's symposium, a…
The publication describes the discovery of a novel series of Imidazopyrazine derivatives by IRBM’s drug discovery team. This novel series of SHP2 allosteric inhibitors, having an imidazopyrazine 6,5-fused heterocyclic system as central scaffold, showed an excellent potency in enzyme and cellular assays.
In a collaboration with Istituto Superiore di Sanità and CNR, IRBM has published research that identified new molecules which block the transmission of the malaria parasite from an infected person to the mosquito, the first step in developing new drugs…
This month Genetic Engineering & Biotechnology News features IRBM in an article about ‘Image-based high-content screening and predictive cell-based assays for drug discovery and development.’
Zika virus (ZIKV) is a member of the Flaviviridae family that can cause neurological disorders and congenital malformations.
We are delighted to publish our first paper of 2022 in the Journal of Pharmaceutical and Biomedical Analysis (Elsevier). Here we leveraged our peptide #ADME toolbox to gain a better understanding of the interplay between oligomerization, albumin binding and catabolism of lipidated peptides in the subcutaneous compartment, using #GLP-1 analogs as model peptides.
Following the first report in the Journal of Medicinal Chemistry in 2020, the IRBM peptide chemistry group is proud to announce a new publication on second generation, potent bi- and tricyclic PCSK9 inhibitor peptides in collaboration with the extraordinary drug…
Our Peptide Chemistry team, in collaboration with scientists at Merck & Co., Inc., Rahway, NJ, USA, reported on the design, synthesis and characterization of potent and stable peptides able to inhibit the binding of NRF2-MAFG heterodimeric transcription factor to Antioxidant…
UniQure has just published a study in Science Translational Medicine using a Huntingtin (HTT)-lowering therapy. IRBM is delighted to have been able to contribute to this pivotal work and to be cited on the publication. Huntingtin is the gene that…
Our integrated drug discovery efforts on the Relaxin-2 peptide hormone, in collaboration with our collaborators at global life sciences company Sanofi, has produced a paper just published in the Journal of Medicinal Chemistry. The natural peptide hormone human relaxin-2 has…